LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis

Background: Dual homeoboxes A pseudogene 8 ( DUXAP8 ) is a newly discovered long noncoding RNA that has been shown to function as an oncogene in a variety of human malignant cancers. By integrating available data, this meta-analysis sought to determine the relationship between clinical prognosis and...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in genetics 2022-08, Vol.13, p.907774-907774
Main Authors: Wang, Yongfeng, Jiang, Xianglai, Zhang, Dongzhi, Zhao, Yuanbin, Han, Xiaoyong, Zhu, Lihui, Ren, Jingyao, Liu, Yubin, You, Jiarong, Wang, Haolan, Cai, Hui
Format: Article
Language:English
Subjects:
bioinformatics analysis
cancers
DUXAP8
Genetics
long noncoding RNA
prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Dual homeoboxes A pseudogene 8 ( DUXAP8 ) is a newly discovered long noncoding RNA that has been shown to function as an oncogene in a variety of human malignant cancers. By integrating available data, this meta-analysis sought to determine the relationship between clinical prognosis and DUXAP8 expression levels in diverse malignancies. Materials and methods: A systematic search was performed to identify eligible studies from several electronic databases from their inception to 25 October 2021. Pooled odds ratios and hazard ratios with 95% CI were used to estimate the association between DUXAP8 expression and survival. For survival analysis, the Kaplan-Meier method and COX analysis were used. Furthermore, we utilized Spearman’s correlation analysis to explore the correlation between DUXAP8 and tumor mutational burden (TMB), microsatellite instability (MSI), the related genes of mismatch repair (MMR), DNA methyltransferases (DNMTs), and immune checkpoint biomarkers. Results: Our findings indicated that overexpression of DUXAP8 was related to poor overall survival (OS) (HR = 1.63, 95% CI, 1.49–1.77, p < 0.001). In addition, elevated DUXAP8 expression was closely related to poor OS in several cancers in the TCGA database. Moreover, DUXAP8 expression has been associated with TMB, MSI, and MMR in a variety of malignancies. Conclusion: This study revealed that DUXAP8 might serve as a prognostic biomarker and potential therapeutic target for cancer. It can be used to improve cancer diagnosis, discover potential treatment targets, and improve prognosis.
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2022.907774